Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1252796

Mesenchymal stromal cells: potential option for COVID-19 treatment


Primorac, Dragan; Čemerin, Martin; Matišić, Vid; Molnar, Vilim; Strbad, Marko; Girandon, Lenart; Zenić, Lucija; Knežević, Miomir; Minger, Stephen; Polančec, Denis
Mesenchymal stromal cells: potential option for COVID-19 treatment // Pharmaceutics, 13 (2021), 9; 1481, 14 doi:10.3390/pharmaceutics13091481 (međunarodna recenzija, pregledni rad, znanstveni)


CROSBI ID: 1252796 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Mesenchymal stromal cells: potential option for COVID-19 treatment
(Mesenchymal stromal cells: potential option for COVID-19 treatment)

Autori
Primorac, Dragan ; Čemerin, Martin ; Matišić, Vid ; Molnar, Vilim ; Strbad, Marko ; Girandon, Lenart ; Zenić, Lucija ; Knežević, Miomir ; Minger, Stephen ; Polančec, Denis

Izvornik
Pharmaceutics (1999-4923) 13 (2021), 9; 1481, 14

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
COVID-19 ; mesenchymal stromal cells ; MSCs ; immunomodulation ; ARDS

Sažetak
The COVID-19 pandemic has significantly impacted the way of life worldwide and continues to bring high mortality rates to at-risk groups. Patients who develop severe COVID-19 pneumonia, often complicated with ARDS, are left with limited treatment options with no targeted therapy currently available. One of the features of COVID- 19 is an overaggressive immune reaction that leads to multiorgan failure. Mesenchymal stromal cell (MSC) treatment has been in development for various clinical indications for over a decade, with a safe side effect profile and promising results in preclinical and clinical trials. Therefore, the use of MSCs in COVID-19-induced respiratory failure and ARDS was a logical step in order to find a potential treatment option for the most severe patients. In this review, the main characteristics of MSCs, their proposed mechanism of action in COVID-19 treatment and the effect of this therapy in published case reports and clinical trials are discussed.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Farmacija



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Zagreb,
Medicinski fakultet, Split,
Medicinski fakultet, Osijek,
Dječja bolnica Srebrnjak,
Specijalna bolnica Sv. Katarina,
Fakultet za dentalnu medicinu i zdravstvo, Osijek

Profili:

Avatar Url Lucija Zenić (autor)

Avatar Url Denis Polančec (autor)

Avatar Url Dragan Primorac (autor)

Avatar Url Vilim Molnar (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Primorac, Dragan; Čemerin, Martin; Matišić, Vid; Molnar, Vilim; Strbad, Marko; Girandon, Lenart; Zenić, Lucija; Knežević, Miomir; Minger, Stephen; Polančec, Denis
Mesenchymal stromal cells: potential option for COVID-19 treatment // Pharmaceutics, 13 (2021), 9; 1481, 14 doi:10.3390/pharmaceutics13091481 (međunarodna recenzija, pregledni rad, znanstveni)
Primorac, D., Čemerin, M., Matišić, V., Molnar, V., Strbad, M., Girandon, L., Zenić, L., Knežević, M., Minger, S. & Polančec, D. (2021) Mesenchymal stromal cells: potential option for COVID-19 treatment. Pharmaceutics, 13 (9), 1481, 14 doi:10.3390/pharmaceutics13091481.
@article{article, author = {Primorac, Dragan and \v{C}emerin, Martin and Mati\v{s}i\'{c}, Vid and Molnar, Vilim and Strbad, Marko and Girandon, Lenart and Zeni\'{c}, Lucija and Kne\v{z}evi\'{c}, Miomir and Minger, Stephen and Polan\v{c}ec, Denis}, year = {2021}, pages = {14}, DOI = {10.3390/pharmaceutics13091481}, chapter = {1481}, keywords = {COVID-19, mesenchymal stromal cells, MSCs, immunomodulation, ARDS}, journal = {Pharmaceutics}, doi = {10.3390/pharmaceutics13091481}, volume = {13}, number = {9}, issn = {1999-4923}, title = {Mesenchymal stromal cells: potential option for COVID-19 treatment}, keyword = {COVID-19, mesenchymal stromal cells, MSCs, immunomodulation, ARDS}, chapternumber = {1481} }
@article{article, author = {Primorac, Dragan and \v{C}emerin, Martin and Mati\v{s}i\'{c}, Vid and Molnar, Vilim and Strbad, Marko and Girandon, Lenart and Zeni\'{c}, Lucija and Kne\v{z}evi\'{c}, Miomir and Minger, Stephen and Polan\v{c}ec, Denis}, year = {2021}, pages = {14}, DOI = {10.3390/pharmaceutics13091481}, chapter = {1481}, keywords = {COVID-19, mesenchymal stromal cells, MSCs, immunomodulation, ARDS}, journal = {Pharmaceutics}, doi = {10.3390/pharmaceutics13091481}, volume = {13}, number = {9}, issn = {1999-4923}, title = {Mesenchymal stromal cells: potential option for COVID-19 treatment}, keyword = {COVID-19, mesenchymal stromal cells, MSCs, immunomodulation, ARDS}, chapternumber = {1481} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font